FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

by The Medical News • 2014/09/16 • 0 Comments

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

← Nicox to acquire Doliage for €5 million in newly issued stock

Allergan to hold special stockholders meeting Dec. 18 without restriction →

Post navigation